Large Companies Eye Collaboration as Entry into AI

Edwards Lifesciences is delving deeper into the realm of artificial intelligence through a partnership with San Francisco-based Bay Labs. The goal of the collaboration, which has multiple initiatives is to improve the detection of heart disease. Some of the initiatives include, the development of new AI-powered algorithms in Bay Labs’ EchoMD measurement and interpretation software suite; support for ongoing clinical studies at institutions; and the integration of EchoMD algorithms into Edwards Lifesciences’ CardioCare quality care navigation platform. Irvine, CA-based Edwards’ CardioCare program combines clinical consulting expertise with a cloud-based platform to facilitate in the identification, referral, and care pathway management of patients with structural heart disease. CardioCare can help hospitals improve quality by reducing variability in echocardiography and ensure effective communication between care settings to ensure patients access to care. Multiple EchoMD algorithms have been integrated into the CardioCare platform for investigational use to retrospectively analyze echocardiograms. In a release the companies said they believe that by incorporating these and future algorithms into clinical practice could help drive quality improvement and potentially increase accurate heart disease detection. Want to hear about more trends in medtech? Check out the Webinar titled "Medtech Trends Innovation and Adaptation"&Ac...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Cardiovascular Source Type: news